Neutrophil extracellular traps induced by activated platelets as a cause of neutrophil–platelet aggregation in β‐thalassaemia/haemoglobin E patients Authors: Rattanawan Thubthed, Rattanaporn Praneetponkang, Potchaman Sittipaisankul, Chayada Thiengtavor, Suwathida Chumpuchanaphai, Kittiphong Paiboonsukwong, Suthat Fucharoen, Kovit Pattanapanyasat, Jim Vadolas, Duncan R. Smith, Saovaros Svasti, Pornthip Chaichompoo Published: 2026 ABSTRACT SummaryThe hypercoagulable state is a major contributor to thromboembolic events and mortality in β‐thalassaemia. The mechanisms underlying platelet‐induced neutrophil activation leading to immunothrombosis remain poorly understood. Three‐dimensional confocal microscopy demonstrated that platelets induced neutrophil extracellular trap (NET) formation through P‐selectin‐ or high mobility group box 1 protein (HMGB1)‐mediated binding to P‐selectin glycoprotein ligand‐1 (PSGL‐1) or receptor for advanced glycation end products (RAGE), respectively, on neutrophils. Molecular signalling pathways involved in NETs—focusing on mitogen‐activated protein kinase kinase (MAPKK) or mitogen‐activated protein kinase kinase 1/2 (MAP2K) (MEK)/extracellular signal–regulated kinase (ERK), reactive oxygen species (ROS), ofnicotinamide adenine dinucleotide phosphate (NADPH) oxidase complex 2 (NOX2), myeloperoxidase (MPO) and peptidylarginine deiminase 4 (PAD4)—were investigated in neutrophils from β‐thalassaemia/haemoglobin E (HbE) patients (splenectomy and non‐splenectomy) and from normal subjects by priming neutrophils with specific inhibitors before treatment with either platelets, recombinant P‐selectin or disulphide HMGB1. In splenectomised patients, neutrophils primed with U0126, but not an ERK inhibitor, exhibited reduced web‐like NETs and cell aggregation, associated with antioxidant effects. In non‐splenectomised patients and normal subjects, P‐selectin activated MEK/ERK, NOX2, MPO and PAD4 pathways, promoting web‐like NETs and cell aggregation. HMGB1 activated neutrophils via MEK/ERK, NOX2, MPO and PAD4 pathways, in all groups, resulting in NETs without aggregation‐associated NET morphology. These findings indicate that splenectomy alters P‐selectin and HMGB1 expression on platelets, leading to altered signalling dynamics in neutrophils and promoting neutrophil–platelet aggregation. ROS pathway could be a key regulator of NET‐driven thrombosis in splenectomised β‐thalassaemia/HbE disease and highlight its potential as a therapeutic target. Abbreviations β‐thalassaemia/HbE extracellular signal–regulated kinase high mobility group box 1 protein mitogen‐activated protein kinase kinase (MAPKK) or mitogen‐activated protein kinase kinase 1/2 (MAP2K) myeloperoxidase neutrophil elastase NADPH oxidase complex 2 peptidylarginine deiminase 4 P‐selectin glycoprotein ligand‐1 receptor for advanced glycation end products reactive oxygen species INTRODUCTION Thromboembolic events are one of the major complications leading to significant morbidity and mortality in β‐thalassaemia, especially in splenectomised patients. These patients have an increased risk of both venous thrombosis and arterial thrombosis such as cerebral thrombosis, deep venous thrombosis, pulmonary embolism and recurrent arterial occlusion. 1 , 2 Platelets are hypersensitive to agonists and rapidly activate 3 and are in a chronic activated state with increased P‐selectin expression. 4 , 5 Importantly, patients who have anti‐platelet activation or who have received regular blood transfusion with iron chelation still develop pulmonary hypertension and thrombosis. 6 In addition, several abnormalities in neutrophils from β‐thalassaemia/haemoglobin E (HbE) patients have been reported, including reduced PU.1 expression, which functions as a transcription factor regulating ofnicotinamide adenine dinucleotide phosphate (NADPH) oxidase complex 2 (NOX2) subunits 7 and neutrophil maturation 8 ; hyposegmented morphology indicative of immaturity and impaired function; and decreased chemotaxis and opsonophagocytosis. 9 , 10 Defects in the myeloid lineage, such as increased circulating myeloid‐derived suppressor cells (MDSCs) associated with chronic inflammation, have been reported, particularly in splenectomised patients. 11 Furthermore, neutrophils from these patients exhibit elevated intracellular reactive oxygen species (ROS) 12 and aberrant neutrophil extracellular trap (NET) formation upon stimulation with phorbol 12‐myristate 13‐acetate and lipopolysaccharide, 13 used as mimics of infection, which may contribute to a reduced capacity to control bacterial spread during infection or septicaemia. Aberrant neutrophil function and chronic platelet activation could mediate the complex process of immunothrombosis in β‐thalassaemia/HbE patients; however, the underlying mechanisms remain unclear. Immunothrombosis links coagulation and immunity, leading to arterial and venous thrombosis. 14 , 15 Neutrophils and platelets are key mediators, particularly in severe sepsis and chronic inflammation, including cancer 14 , 16 , 17 , 18 , 19 , 20 Neutrophils release NETs which not only trap microbes at infection sites but also promote thrombosis by providing a scaffold for platelets, coagulation factors, red blood cells and endothelium. During vascular repair, activated platelets express proteins such as P‐selectin and high mobility group box 1 (HMGB1), promoting clot formation. Platelets may also activate neutrophils and induce NET formation via P‐selectin–P‐selectin glycoprotein ligand‐1 (PSGL1) and HMGB1–the receptor for advanced glycation end products (RAGE) interactions. 21 , 22 , 23 , 24 , 25 Binding activates mitogen‐activated protein kinase kinase (MAPKK) or mitogen‐activated protein kinase kinase 1/2 (MAP2K) (MEK)/extracellular signal–regulated kinase (ERK) (MEK/ERK) and ROS signalling, leading to NOX2 activation and myeloperoxidase (MPO) production. MPO promotes neutrophil elastase (NE) translocation, driving chromatin decondensation, while peptidylarginine deiminase 4 (PAD4)‐mediated histone citrullination further facilitates this process. 26 The nuclear membrane then breaks down, chromatin mixes with granule proteins and the cell ruptures to release web‐like NETs. 19 , 26 , 27 , 28 , 29 However, NETs may occur without deoxyribonucleic acid (DNA) release, producing diffuse (non–web‐like) forms. 26 , 29 Thus, NOX2‐ and PAD4‐dependent pathways are not exclusive, and NET morphology may relate to clinical presentation. This study aimed to investigate whether neutrophils from β‐thalassaemia/HbE patients exhibit an abnormal response to activated platelets or engage different pathways as compared to normal neutrophils. This aberrant response could lead to enhanced NET formation, contributing to neutrophil–platelet aggregation and driving the hypercoagulable state in β‐thalassaemia/HbE patients. MATERIALS AND METHODS Subjects Peripheral blood samples were collected from β‐thalassaemia/HbE patients, who were divided into splenectomised and non‐splenectomised groups, and normal subjects, with ages ranging from 18 to 63 years. All patients received folic acid (5 mg) daily. All subjects had no evidence of concurrent infection, and none had been hospitalised or transfused within the preceding 4 weeks. Blood samples were collected in tripotassium ethylenediaminetetraacetic acid (K3EDTA) for a full blood count and thalassaemia diagnosis, in a clot blood tube for serum ferritin and in a citrate‐phosphate‐dextrose‐adenine solution 1 for P‐selectin expression, HMGB1 levels, neutrophil and platelet isolation. Samples were kept at room temperature (RT) and processed within 1 h. Platelet isolation and HMGB1 measurement Whole blood samples were centrifuged at 1000 rpm for 10 min at RT to obtain platelet‐rich plasma, which was then centrifuged at 14 000 g for 2 min at 4°C. The sediment was collected as isolated platelets. The isolated platelets were washed once with 1× phosphate buffered saline (PBS) (Hyclone, Logan, UT) and counted by flow cytometry. The supernatant was collected as platelet‐free plasma (PFP) for HMGB1 measurement using a Human HMGB1 enzyme‐linked immunosorbent assay (ELISA) Kit (Elabscience Biotechnology Co., Ltd., Houston, TX), according to the manufacturer's instructions. Flow cytometric analysis of P‐selectin expression and platelet counts Diluted whole blood (1:10) or isolated platelets were stained with fluorochrome‐conjugated monoclonal antibodies against CD41a and/or CD62P (P‐selectin) in 1× PBS. Stained samples were added, with a known volume and dilution factor, to TruCount tubes (BD Biosciences, San Jose, CA) for absolute quantification. Samples were analysed using a BD FACScan flow cytometer with BD CellQuest Pro software (BD Biosciences). 30 Details of the antibodies are provided in Table S1. Neutrophil isolation Peripheral blood neutrophils were isolated as previously described. 13 Briefly, whole blood samples were centrifuged by gradient centrifugation using Lymphoprep solution (Fresenius/Axis‐Shield PoC AS, Oslo, Norway) to remove mononuclear cells. The neutrophil‐red blood cell fraction was then separated using a 6% dextran solution (Sigma‐Aldrich, St Louis, MO). Isolated neutrophils were washed and resuspended in RPMI1640 media (Gibco, Paisley, UK) and counted using trypan blue dye (Gibco) and/or 3% acetic acid with methylene blue (Stem cell technologies, Vancouver, Canada). Neutrophil purity was determined by staining with fluorochrome‐conjugated monoclonal antibodies specific to CD13 (neutrophil marker), CD45 (leucocyte marker) and CD235a (red cell marker) (Table S1). Data were acquired using a BD FACScan flow cytometer and analysed with BD CellQuestPro software. NOX2 messenger ribonucleic acid expression in isolated neutrophils Expression of NOX2 subunits was determined by reverse transcription‐quantitative polymerase chain reaction (RT‐qPCR). Total ribonucleic acid (RNA) was extracted from isolated neutrophils, and cDNA was synthesised from 500 ng RNA using a MultiScribe™ high‐capacity cDNA reverse transcription kit (Applied Biosystems, Waltham, MA). RT‐qPCR was performed using iTaq™ universal SYBR® Green supermix (Bio‐Rad Laboratories, Hercules, CA) on an ABI 7500 system (Applied Biosystems). Primer sequences are listed in Table S2. Gene expression was normalised to glyceraldehyde 3‐phosphate dehydrogenase, and relative expression was calculated using the 2−ΔΔCt method, expressed as fold change relative to normal subjects. Neutrophil–platelet co‐incubation, PFP‐cultured neutrophils and NET inhibition and induction treatments Isolated neutrophils (1.5 × 105 cells) were co‐incubated with isolated platelets (1.5 × 106 cells) at a 1:10 ratio in Roswell Park Memorial Institute (RPMI) 1640 medium in a 24‐well plate containing coverslip coated with 0.01% poly‐L‐lysine solution (Sigma‐Aldrich) for 90 min at 37°C, 5%CO2. For PFP‐cultured neutrophils, neutrophils (5 × 105 cells) were seeded onto coated coverslip (∅12 mm, area 113.1 mm2) in a 24‐well plate and cultured in PFP from splenectomised β‐thalassaemia/HbE patients or normal subjects for 90 min at 37°C, 5% CO2. For inhibitor studies, neutrophils (5 × 105 cells) were pretreated for 30 min at 37°C, 5% CO2 with 1 μM U0126 (Cell Signaling Technology, Danvers, MA), 2 μM ERK inhibitor peptide II (Calbiochem, San Diego, CA), 1 μM diphenyl iodonium (DPI, an NADPH oxidase inhibitor) (Sigma‐Aldrich), 50 μM MPO inhibitor II (Calbiochem) or 10 μM BB‐Cl‐amidine (a PAD4 inhibitor) (Cayman Chemical, Ann Arbor, MI) in RPMI 1640 medium. Primed neutrophils were then stimulated with 500 ng/mL recombinant P‐selectin (R&D Systems, Minneapolis, MN) or 100 ng/mL recombinant disulphide HMGB1 (HMGbiotech, Milano, Italy) for 90 min at 37°C, 5% CO2. Untreated neutrophils served as baseline controls, while neutrophils stimulated with recombinant P‐selectin or recombinant disulphide HMGB1 served as positive controls. Confocal microscopy analysis of co‐localisation, NETs and cell–cell aggregation Co‐incubated neutrophils and platelets, PFP or NET inhibition and induction treatments were gently washed and fixed with 4% paraformaldehyde (Sigma‐Aldrich), washed with 1% bovine serum albumin (BSA) in PBS and permeabilised with 0.1% Triton X‐100. Samples were then blocked with 2% human AB serum for 2 h at RT. For co‐localisation studies, samples were incubated overnight at 4°C with cocktail primary antibodies specific to PSGL‐1 and P‐selectin, or RAGE and HMGB1 (Table S1). For NET and aggregation analysis, samples were incubated with cocktail primary antibodies specific to CD41a, histone H2A and NE. After washing, samples were incubated with an appropriate cocktail of secondary antibodies for 1 h at RT in the dark, followed by 4′,6‐diamidino‐2‐phenylindole, dihydrochloride (DAPI) (Molecular Probes, OR) staining. Fluorescence images were acquired in z‐stack mode using a super‐resolution laser scanning confocal microscope (Carl Zeiss LSM800 with AiryScan, Carl Zeiss, Oberkochen, Germany) equipped with ZEN 2.1 software. Statistical analysis Data were analysed using SPSS version 18.0 (IBM, Armonk, NY) and GraphPad PRISM 9.0 software (GraphPad Software, Inc., San Diego, CA). Comparisons between parameters were evaluated with a non‐parametric Mann–Whitney U‐test. The correlation coefficient between parameters was calculated with Spearman's correlation coefficient (r s). The threshold for statistical significance for all comparisons was p < 0.05. RESULTS Abnormal neutrophils and platelets play a role in the hypercoagulable state in β‐thalassaemia/HbE disease β‐Thalassaemia/HbE patients had microcytic hypochromic anaemia and iron overload (Table 1). Splenectomised patients had thrombocytosis, while white blood cell counts and absolute neutrophils remained within the reference range. Consequently, the neutrophil‐to‐platelet ratio was approximately fourfold higher in splenectomised patients (mean 1:332, range 1:16 to 1:806) compared with normal subjects. TABLE 1Haematological parameters of subjects in cohort.DescriptionNormal subjectsβ‐Thalassaemia/HbE patientsReference rangeNon‐splenectomySplenectomyNumber (male:female)15 (6:9)15 (7:8)15 (7:8)Age (years) (range)28 ± 3 (23–33)34 ± 16 (18–63)37 ± 10 (24–57)Red blood cell count (×1012/L)4.8 ± 0.54.0 ± 0.9 a 3.0 ± 0.5 b , c 4.2–5.4Haemoglobin (g/dL)13.7 ± 1.97.7 ± 1.6 b 6.6 ± 0.8 b , d 12–18Haematocrit (%)41.2 ± 5.024.0 ± 5.0 b 21.8 ± 2.5 b 37–52MCV (fL)85.2 ± 5.960.8 ± 6.4 b 72.8 ± 6.8 b , e 80–99MCH (pg)28.2 ± 2.519.6 ± 2.4 b 22.0 ± 2.0 b , c 27–31MCHC (g/dL)33.1 ± 0.932.2 ± 1.430.3 ± 1.0 b , e 33–37Red cell distribution width (%)13.8 ± 1.229.6 ± 6.0 b 29.0 ± 4.4 b 11.5–14.5Reticulocyte count (%)1.4 ± 0.53.9 ± 1.3 b 16.6 ± 4.1 b , e 0.9–2.1Reticulocytes (×109/L)69.0 ± 25154.1 ± 57.0 b 470.2 ± 209.2 b , c 35–81NRBCs (cells/100WBCs)0 ± 04.7 ± 5 b 367 ± 272 b , e NonePlatelet count (×109/L)275 ± 63199 ± 118584 ± 108 b , e 140–450Absolute neutrophils (×109/L)3.6 ± 0.84.3 ± 2.16.3 ± 10.51.5–8.0Neutrophil:platelet ratio (mean)1:35 to 1:128 (1:80)1:25 to 1:112 (1:50)1:16 to 1:806 a , c (1:332)WBC count (×109/L)6.2 ± 0.76.9 ± 2.910.4 ± 15.04–10WBC differential countNeutrophils (%)57.2 ± 6.960.8 ± 9.549.0 ± 13.8 d 40–74Lymphocytes (%)34.8 ± 7.032.4 ± 9.439.3 ± 14.619–48Monocytes (%)5.2 ± 2.54.3 ± 1.66.5 ± 4.13–9Eosinophils (%)2.6 ± 2.21.9 ± 1.64.2 ± 3.8 d 0–7Basophils (%)0.2 ± 0.30.4 ± 0.50.8 ± 1.00–2Serum ferritin (ng/mL)58 ± 452521 ± 2040 b 3755 ± 3465 b 32–100 Note: Data presents mean ± SD.Abbreviations: HbE, haemoglobin E; MCH, mean corpuscular haemoglobin; MCHC, mean corpuscular haemoglobin concentration; MCV, mean corpuscular volume; NRBCs, nucleated red blood cells; WBC, corrected white blood cells. a Significantly different when compared to normal subjects at p < 0.05. b Significantly different when compared to normal subjects at p < 0.001. c Significantly different when compared to non‐splenectomised β‐thalassaemia/HbE patients at p < 0.01. d Significantly different when compared to non‐splenectomised β‐thalassaemia/HbE patients at p < 0.05. e Significantly different when compared to non‐splenectomised β‐thalassaemia/HbE patients at p < 0.001. Haematological parameters of subjects in cohort. Note: Data presents mean ± SD. Abbreviations: HbE, haemoglobin E; MCH, mean corpuscular haemoglobin; MCHC, mean corpuscular haemoglobin concentration; MCV, mean corpuscular volume; NRBCs, nucleated red blood cells; WBC, corrected white blood cells. Significantly different when compared to normal subjects at p < 0.05. Significantly different when compared to normal subjects at p < 0.001. Significantly different when compared to non‐splenectomised β‐thalassaemia/HbE patients at p < 0.01. Significantly different when compared to non‐splenectomised β‐thalassaemia/HbE patients at p < 0.05. Significantly different when compared to non‐splenectomised β‐thalassaemia/HbE patients at p < 0.001. Chronic platelet activation in patients was determined by measuring the expression of P‐selectin on platelets from whole blood and HMGB1 from PFP. A twofold to threefold increase in P‐selectin expression on platelets from splenectomised patients (mean ± standard deviation [SD], 13 ± 11% and 79 ± 74 × 109 platelets/L), as measured by flow cytometry and calculated from FBC, respectively, was significantly increased as compared to normal subjects (5 ± 2% and 14 ± 5 × 109 platelets/L) (Figure 1A,B). In addition, HMGB1—present in both soluble and surface‐bound forms—is another hallmark of platelet activation and was elevated in PFP from the patients (1.45 ± 0.45 ng/mL in splenectomised patients and 1.46 ± 0.32 ng/mL in non‐splenectomised patients) compared with normal subjects (1.03 ± 0.27 ng/mL) (Figure 1C). Both P‐selectin and HMGB1 could play important roles in regulating neutrophils to form NETs, leading to thrombosis in thalassaemia. Aberrant neutrophils and platelets in β‐thalassaemia/haemoglobin E (HbE) disease. (A) Fresh whole blood was stained with fluorochrome‐conjugated monoclonal antibodies against CD41a and P‐selectin and analysed by flow cytometry. (A‐i) Platelets were gated in the R1 region; (A‐ii) CD41a+ platelets were selected in R2; and (A‐iii) P‐selectin+CD41a+ platelets were analysed in R3. Cut‐offs were defined using (A‐iv) CD41a single‐stained and (A‐v) unstained controls. (A‐vi) Percentage and (A‐vii) mean fluorescence intensity (MFI) of P‐selectin expression are shown. (B) Absolute platelet numbers were calculated using counts from a haematology analyser. (C) Levels of high mobility group box 1 protein (HMGB1) in platelet‐free plasma (PFP) were measured using a Human HMGB1 ELISA Kit and quantified by comparing the optical density (OD) of unknown samples with a standard curve generated using the HMGB1 standards provided in the kit. (D) Schematic of NADPH oxidase complex 2 (NOX2) subunits (gp91 phox , p22 phox , p40 phox , p47 phox and p67 phox ) involved in superoxide generation in neutrophil granules. (E) p22 phox expression in isolated neutrophils assessed by RT‐qPCR. (F) Spearman's correlation (r s) between p22 phox expression and serum ferritin. (G–J) Expression of other NOX2 subunits (gp91 phox , p47 phox , p67 phox and p40 phox ). Data are presented as mean ± SD. *Significant difference between groups by using Mann–Whitney U‐test, p < 0.05. ns, not significant difference. BE‐NS, non‐splenectomised β‐thalassaemia/HbE patients; BE‐S, Splenectomised patients; FBC, full blood count; and Normal: Normal subjects. The NOX2‐dependent pathway regulates neutrophil phagocytosis and NET formation. gp91 phox and p22 phox form the membrane‐bound core, while p47 phox , p67 phox and p40 phox are cytosolic regulatory subunits that remain in the cytosol in resting neutrophils (Figure 1D). Upon activation, these subunits translocate to the membrane to assemble the active enzyme complex. Their expression levels are more variable and may influence enzymatic activity. Here, we investigated the expression of NOX2 subunits as baseline of neutrophils from β‐thalassaemia/HbE patients and normal subjects (Figure 1E–J). Interestingly, p22 phox , p67 phox and p40 phox were also reduced in neutrophils from splenectomised patients compared to normal subjects. By contrast, increased gp91 phox expression was found in both splenectomised and non‐splenectomised patients. Ferritin levels were found to correlate with p22 phox expression (r s = −0.631, p = 0.012). Therefore, NOX activity and function may be impaired in splenectomised patients, as the complex may fail to assemble properly due to a lack of certain subunits. Initiation of NET formation induced by platelets via PSGL1‐P‐selectin and RAGE‐HMGB1 interactions To address whether P‐selectin and HMGB1 on platelets can induce NET formation via interactions with PSGL‐1 and RAGE respectively. Neutrophils were co‐incubated with platelets and analysed for PSGL1‐P‐selectin and RAGE‐HMGB1 co‐localisation using Mander's co‐localisation coefficiency. 31 The results showed strong colocalisation, with PSGL1‐P‐selectin at 0.8961 ± 0.0297 (mean ± SD, range 0.8216–0.9643) and RAGE‐HMGB1 at 0.9039 ± 0.0232 (range 0.8407–0.9569) (Figure 2A–C). Platelet‐induced neutrophil extracellular traps. (A–H) Neutrophils from normal controls and β‐thalassaemia/haemoglobin E (HbE) patients were co‐incubated with allogeneic platelets for 90 min. Co‐localisation of PSGL1–P‐selectin and RAGE–HMGB1 and the number and size of cell aggregates were analysed by confocal microscopy. (A–C) 3D confocal imaging assessed co‐localisation of (A) PSGL1 (red) on neutrophils with P‐selectin (green) on platelets, and (B) RAGE (red) with HMGB1 (green) (Figure S1). Nuclei were stained with DAPI (blue). Negative controls included single staining (primary and secondary antibodies for each target protein and DAPI alone) and secondary antibody cocktails without primary antibodies. (C) Mander's co‐localisation coefficient with background correction based on selected regions of interest (ROIs), applying a criterion of protein–protein colocalization >0.69 as the cut‐off, 31 was calculated for PSGL1–P‐selectin and RAGE–HMGB1 interactions in individual neutrophil–platelet aggregates (Neu–Plt; n = 78). Experiments used neutrophils from 10 subjects and platelets from five subjects to generate 10 independent experiments. Images from each experiment were captured from 10 different fields, discarding every five fields, using a 63× oil immersion lens on a super‐resolution laser scanning confocal microscope (Carl Zeiss LSM800 with AiryScan, Carl Zeiss, Oberkochen, Germany) equipped with ZEN 2.1 software. (D) Platelet count and P‐selectin expression were determined by flow cytometry. (D‐i) BD TruCount beads (R1) and platelets (R2); (D‐ii) CD41+ platelets were gated and counted according to the manufacturer's instructions; (D‐iii–iv) platelets were double‐stained with CD41a and P‐selectin; (D‐v) unstained control; (D‐vi–vii) percentage and mean fluorescence intensity (MFI) of P‐selectin expression. (E) Neutrophils from normal subjects (Normal), non‐splenectomised (BE‐NS) and splenectomised (BE‐S) patients were incubated with or without platelets to assess cell aggregation. Samples were stained for CD41a (pink), neutrophil elastase (green), histone H2A (red) and DAPI (blue) (Figure S2). Three different zones per experiment were examined, each comprising 20 consecutive fields, using a 63× oil immersion lens on a super‐resolution laser scanning confocal microscope (Carl Zeiss LSM800 with AiryScan) (Figure S3). (F, G) Number and size of cell aggregates were quantified. Untreated neutrophils served as baseline. (H) Spearman's correlation (rₛ) between P‐selectin expression on platelets and (H‐i) aggregate number or (H‐ii) size. (I–L) Neutrophils from normal subjects (n = 5) were incubated with platelet‐free plasma (PFP) from normal subjects (Normal; n = 3) or splenectomised patients (BE‐S) (n = 5) to determine (J) aggregate number and (K) size. Neutrophils cultured in RPMI 1640 medium were used as negative control. (L) Spearman's correlation between HMGB1 and (L‐i) aggregate number or (L‐ii) size. Data present mean ± SD. *Significant difference between group by using Mann–Whitney U‐test, p < 0.05. DAPI, 4′,6‐diamidino‐2‐phenylindole, dihydrochloride; HMGB1, high mobility group box 1 protein; PSGL1, P‐selectin glycoprotein ligand‐1; RAGE, receptor for advanced glycation end products. Isolated platelets were counted and P‐selectin expression determined by flow cytometry (Figure 2D); however, centrifugation affected P‐selectin expression. Neutrophils obtained from five splenectomised, four non‐splenectomised patients and three normal subjects were co‐incubated with allogeneic platelets to observe the number and the size of cell aggregation by a confocal microscope (Figure 2E). Untreated neutrophils were used as baseline controls, and neutrophils from patients showed spontaneous aggregation. Co‐incubation with allogeneic platelets significantly increased the number of cell aggregates, but not their size (Figure 2F,G). The percentage of P‐selectin+ isolated platelets correlated with aggregate number (r s = 0.712, p < 0.01), but not with aggregate size (Figure 2H). Moreover, PFP containing soluble HMGB1 from three normal subjects and five splenectomised patients was used to culture neutrophils from five normal subjects. Aggregate number and size were analysed by confocal microscopy (Figure 2I). The number of aggregates was significantly increased compared with RPMI 1640 control (Figure 2J), while aggregate size was greater in samples treated with PFP from splenectomised patients (Figure 2K). HMGB1 levels were not correlated with aggregate number but were associated with aggregate size (Figure 2L). These findings suggest that platelet‐induced neutrophil aggregation is mediated, at least in part, by PSGL1‐P‐selectin and RAGE‐HMGB1 signalling pathways. The ROS pathway plays an important role in NET formation in P‐selectin‐induced neutrophils from splenectomised β‐thalassaemia/HbE patients Recombinant P‐selectin induced NETs in neutrophils from patients (81 ± 10% in splenectomised and 87 ± 10% in non‐splenectomised) and normal subjects (75 ± 3%), compared with untreated baseline (Figure 3A–C). NET stages differed between groups (Figure 3A–F). In splenectomised patients, non‐web‐like NETs predominated (41 ± 12%), followed by early NETs (36 ± 18%) and web‐like NETs (23 ± 21%). A similar pattern was observed in normal subjects (50 ± 6%, 35 ± 8% and 15 ± 5% respectively). In contrast, neutrophils from non‐splenectomised patients predominantly formed web‐like NETs (43 ± 12%), followed by non‐web‐like NETs (32 ± 8%) and early NETs (25 ± 8%). Effects of recombinant P‐selectin‐induced NETs in neutrophils from β‐thalassaemia/haemoglobin E (HbE) patients. Neutrophils from normal subjects (n = 5), non‐splenectomised β‐thalassaemia/HbE patients (n = 5) and splene.ctomised patients (n = 5) were pretreated with NET inhibitors: 1 μM U0126 (MEK inhibitor/antioxidant), 2 μM ERK inhibitor peptide II (ERKi), 1 μM diphenyl iodonium (DPI; NADPH oxidase inhibitor), 50 μM MPO inhibitor II (MPOi), or 10 μM BB‐Cl‐amidine (PAD4 inhibitor) for 30 min at 37°C, 5% CO2. Neutrophils were then stimulated with 500 ng/mL recombinant P‐selectin. Untreated neutrophils served as baseline controls, and P‐selectin‐treated neutrophils as positive NET controls (Figure S4). (A) Neutrophils were stained for neutrophil elastase (NE; green), histone H2A (red) and DAPI (blue) and analysed by confocal microscopy. Each image represents a zone of 20 contiguous fields acquired with a 63× oil immersion lens in Z‐stack mode using a super‐resolution confocal microscope (LSM800 with AiryScan, Carl Zeiss) and ZEN 2.1 software. (B–F) One hundred non‐aggregated neutrophils were counted and classified into NET stages. 13 (B) Mean percentage of each stage across conditions. Individual data are shown as (C) total NET‐positive neutrophils, subdivided into late‐stage NETs: (D) web‐like and (E) non–web‐like, and (F) early‐stage NETs. (G) The number of cell–cell aggregates under each condition was quantified by outlining aggregates and measuring their area in μm2. (H) Spearman's correlation (rₛ) between web‐like late NETs and the number of cell–cell aggregates in P‐selectin‐treated neutrophils. Data are presented as mean ± SD. #Significant difference between groups when compared to untreated neutrophils using Mann–Whitney U‐test at p < 0.05. *Significant difference between groups when compared to P‐selectin treatment using Mann–Whitney U‐test at p < 0.05. Individual group data are shown in Figures S5 and S6. ERK, extracellular‐signal‐regulated kinase; HMGB1, high mobility group box 1 protein; MEK, mitogen‐activated protein kinase kinase (MAPKK) or mitogen‐activated protein kinase kinase 1/2 (MAP2K); MPO, myeloperoxidase; NET, neutrophil extracellular trap; PAD4, peptidylarginine deiminase 4. Inhibition of the MEK, ERK, NOX2, MPO and PAD4 pathways reduced P‐selectin‐induced NET formation in neutrophils from normal subjects (Figure S4); inhibition of NOX2 and PAD4 also decreased cell aggregation (Figure 3G). In non‐splenectomised patients, the MEK/ERK pathway could be key in regulating NET formation, although inhibition of NOX2, MPO and PAD4 reduced web‐like NETs. In splenectomised patients, U0126 reduced NET formation and aggregation following P‐selectin treatment, whereas ERK inhibition had no effect on NET morphology. As U0126 blocks MEK activity and prevents ERK phosphorylation, these findings suggest that its effects may relate more to antioxidant properties than to MEK inhibition. All inhibitors significantly reduced cell aggregation in patient neutrophils. Web‐like NETs correlated strongly with aggregate number (r s = 0.773, p = 0.001), indicating a key role in thrombus formation (Figure 3H). Overall, P‐selectin–PSGL‐1 interaction likely promotes ROS‐dependent, web‐like NET formation, contributing to thrombosis in splenectomised β‐thalassaemia/HbE patients. The MEK/ERK and NOX2‐PAD4 pathways play important roles in NET formation in HMGB1‐induced neutrophils from splenectomised β‐thalassaemia/HbE patients Similar to P‐selectin, recombinant disulphide HMGB1 induced NET and cell aggregation in β‐thalassaemia/HbE patients and normal subjects with a similar pattern of NET stages: with early NETs and non‐web‐like NETs as the majority, followed by web‐like NETs (Figure 4A–F). In normal subjects, the total number of NETs, particularly web‐like NETs, was significantly reduced when neutrophils were primed with MEK, ERK or PAD4 inhibitors prior to stimulation with recombinant disulphide HMGB1. Effects of recombinant disulphide HMGB1‐induced NETs in neutrophils from β‐thalassaemia/haemoglobin E (HbE) patients. Neutrophils from normal subjects (n = 5), non‐splenectomised β‐thalassaemia/HbE patients (n = 5) and splenectomised patients (n = 5) were pre‐treated with NET inhibitors: 1 μM U0126 (MEK inhibitor/antioxidant), 2 μM ERK inhibitor peptide II (ERKi), 1 μM diphenyl iodonium (DPI; NADPH oxidase inhibitor), 50 μM MPO inhibitor II (MPOi), or 10 μM BB‐Cl‐amidine (PAD4 inhibitor) for 30 min at 37°C, 5% CO2. Neutrophils were then stimulated with 100 ng/mL recombinant disulphide HMGB1. Untreated neutrophils served as baseline controls, and disulphide HMGB1‐treated neutrophils as positive NET controls (Figure S4). (A) Neutrophils were stained for neutrophil elastase (NE; green), histone H2A (red) and DAPI (blue) and analysed by confocal microscopy. Each image represents a zone of 20 contiguous fields acquired with a 63× oil immersion lens in Z‐stack mode using a super‐resolution confocal microscope (LSM800 with AiryScan, Carl Zeiss) and ZEN 2.1 software. (B–F) One hundred non‐aggregated neutrophils were counted and classified into NET stages. (B) Mean percentage of each stage across conditions. Individual data are shown as (C) total NET‐positive neutrophils, subdivided into late‐stage NETs: (D) web‐like and (E) non‐web‐like, and (F) early‐stage NETs. 13 (G) The number of cell–cell aggregates under each condition was quantified. (H) Spearman's correlation (rₛ) between web‐like late NETs and the number of cell–cell aggregates in disulphide HMGB1‐treated neutrophils. Data are presented as mean ± SD. #Significant difference between groups when compared to untreated neutrophils using Mann–Whitney U‐test at p < 0.05. *Significant difference between groups when compared to disulphide HMGB1 treatment using Mann–Whitney U‐test at p < 0.05. Individual group data are shown in Figures S5 and S7. ERK, extracellular‐signal‐regulated kinase; HMGB1, high mobility group box 1 protein; MEK, mitogen‐activated protein kinase kinase (MAPKK) or mitogen‐activated protein kinase kinase 1/2 (MAP2K); MPO, myeloperoxidase; NET, neutrophil extracellular trap; PAD4, peptidylarginine deiminase 4. In non‐splenectomised patients, all inhibitors—especially U0126, a MEK inhibitor—significantly reduced the formation of both web‐like and non‐web‐like NETs. In splenectomised patients, web‐like NETs and early NETs were the predominant morphologies observed when neutrophils were primed with MEK, ERK, NOX2 or PAD4 inhibitors before HMGB1 treatment. However, inhibitors targeting MEK, ERK, NOX2, MPO and PAD4 shown significantly reduced the number of cell aggregation compared to HMGB1‐treated unprimed neutrophils in all groups (Figure 4G). Unlike P‐selectin treatment, there was no correlation between the number of web‐like NETs and cell aggregation under disulphide HMGB1 treatment (Figure 4H). DISCUSSION The hypercoagulable state in β‐thalassaemia/HbE patients, especially those who have undergone splenectomy, is associated with a high risk of thromboembolism. Elevated levels of P‐selectin and HMGB1 in the blood circulation are hallmarks of chronic platelet activation in patients and play a crucial role in inducing NET formation, leading to thrombosis. In this study, we dissected the pathways involving in NETs regulated by P‐selectin and HMGB1 on activated platelets to better understand the pathomechanism of the hypercoagulable state in thalassaemia. The role of P‐selectin in inducing NET formation in neutrophils via interaction with PSGL‐1 was demonstrated by the inhibition of NET formation following treatment with anti‐PSGL‐1 in P‐selectin‐treated neutrophils. 21 , 32 , 33 Neutrophils from splenectomised patients showed a distinct response to recombinant P‐selectin compared to neutrophils from non‐splenectomised patients and normal subjects (Figure 5A). The interaction between PSGL‐1 and P‐selectin can rapidly induce tyrosine phosphorylation of multiple proteins. 34 , 35 Among the five pathways investigated in this study—MEK/ERK, ROS, NOX2, MPO and PAD4—showed no relevance or cross‐talk with each other, which was surprising, particularly for the MEK/ERK and NOX2/MPO pathways. Inhibition of MEK1 and MEK2 kinases using U0126 clearly affected web‐like NET formation and clot development in splenectomised patients. Regulation of P‐selectin and HMGB1 in NET induction in thalassaemic neutrophils. (A) Neutrophils from splenectomised β‐thalassaemia/haemoglobin E (HbE) patients exhibited a defective NOX2 subunit. Activation of splenectomised β‐thalassaemia/HbE neutrophils by P‐selectin via PSGL‐1 led to ROS involvement in inducing web‐like late NET formation, ultimately resulting in cell aggregation. In contrast, HMGB1‐induced activation of splenectomised β‐thalassaemia/HbE neutrophils involved the MEK/ERK, NOX2 and PAD4 pathways, leading to clot formation independently of NET stages. (B) In non‐splenectomised β‐thalassaemia/HbE patients, P‐selectin primarily induced web‐like late NET formation via the MEK/ERK pathway. However, NOX2, PAD4 and MPO also contributed to web‐like late NET formation. Unlike P‐selectin, HMGB1 interacted with RAGE, directly affecting MEK as the primary regulator of NET formation. Nevertheless, ERK, NOX2, PAD4 and MPO were also involved in web‐like late NET and clot formation. ERK, MEK‐extracellular‐signal‐regulated kinase; HMGB1, high mobility group box 1 protein; MEK, mitogen‐activated protein kinase kinase (MAPKK) or mitogen‐activated protein kinase kinase 1/2 (MAP2K); MPO, myeloperoxidase; NET, neutrophil extracellular trap; NOX2, NADPH oxidase complex 2; PAD4, peptidylarginine deiminase 4; PSGL‐1, P‐selectin glycoprotein ligand‐1; RAGE, receptor for advanced glycation end products; ROS: reactive oxygen species. Illustration by Pornthip Chaichompoo. Although U0126 is widely used as a MEK pathway inhibitor, it can also influence multiple molecular signalling pathways including MEK/ERK, c‐Jun N‐terminal kinase (JNK), Kirsten rat sarcoma viral oncogene homologue (KRAS), P44/42, Janus kinase/Signal transducer and activator of transcription (JAK/STAT), Phosphoinositide 3‐kinase/ Protein Kinase B/Mammalian Target of Rapamycin (PI3K/AKT/mTOR) and Rat sarcoma/Rapidly accelerated fibrosarcoma/Extracellular signal‐regulated kinase (Ras/Raf/ERK) signalling pathways 36 and antioxidant properties. 37 Additionally, inhibiting ERK, NOX2 and PAD4, despite not affecting NET morphology, reduced cell aggregation in splenectomised patients. MEK's function is to phosphorylate ERK, and signalling pathways such as JNK, KRAS, P44/42, JAK/STAT, PI3K/AKT/mTOR and Ras/Raf are downstream of ERK. Therefore, the reduction of ROS likely represents the primary role of U0126 in neutrophils from splenectomised patients in regulating NET formation. In non‐splenectomised patients, the MEK/ERK pathway primarily regulated web‐like NETs when neutrophils were activated with P‐selectin. Moreover, the NOX2, MPO and PAD4 pathways were also associated with NET morphology and cell aggregation (Figure 5B). HMGB1‐mediated RAGE signalling plays a key role in neutrophil responses during bacterial killing and inflammation. 38 , 39 Inhibition of RAGE using anti‐RAGE agents has been shown to reduce NETs. 40 , 41 HMGB1 stimulation may enhance neutrophil HMGB1 production, amplifying acute inflammation. 42 Inhibition of the MEK/ERK pathway using U0126 and ERK inhibitor effectively reduced NET and cell aggregation in both splenectomised and non‐splenectomised patients in this study. Herein, the molecular mechanism by which platelet‐expressed P‐selectin or HMGB1 initiates the NET pathway through binding to PSGL‐1 or RAGE, respectively, on neutrophils in β‐thalassaemia/HbE disease was investigated, as further understanding could help clarify the hypercoagulable state in thalassaemia and support the potential use of a novel therapeutic approach to reduce the risk to thromboembolic events. These mechanisms might apply to other thromboinflammatory diseases like sepsis, Coronavirus disease 2019 or autoimmune vasculitis. In addition, these findings suggest two main novel approaches for the prevention and treatment of thrombosis in β‐thalassaemia. First, prevent platelet activation by inhibiting platelet activation using low‐dose aspirin as commonly used, P‐selectin blockers, anti‐P‐selectin or anti‐HMGB1 antibodies; and reducing stress by using antioxidants such as N‐acetylcysteine, vitamin C and vitamin E. 43 Second, inhibit NET formation pathways by targeting ROS using antioxidants and MEK pathway using inhibitors such as PD0325901 Food and Drug Administration (FDA approved) or U0126 36 ; and degrading extracellular DNA using DNase I (FDA approved). In summary, splenectomised β‐thalassaemia/HbE patients exhibit chronic platelet activation characterised by elevated P‐selectin and HMGB1 levels that interact with neutrophils via PSGL‐1 and RAGE respectively. These pathways promote NET formation through ROS and the MEK/ERK signalling. Clinically, monitoring P‐selectin and HMGB1 levels may help guide the use of antioxidant, anti‐platelet or anti‐NET therapies to prevent thrombosis in β‐thalassaemia. AUTHOR CONTRIBUTIONS Rattanaporn Praneetponkang: Investigation; validation; formal analysis. Chayada Thiengtavor: Investigation; validation. Rattanawan Thubthed: Investigation; writing – original draft; validation; formal analysis. Suwathida Chumpuchanaphai: Investigation; validation. Saovaros Svasti: Conceptualization; methodology; writing – review and editing; supervision; project administration; resources. Potchaman Sittipaisankul: Investigation; validation. Duncan R. Smith: Conceptualization; methodology; writing – review and editing; supervision. Kittiphong Paiboonsukwong: Conceptualization; investigation. Suthat Fucharoen: Conceptualization; investigation. Kovit Pattanapanyasat: Conceptualization; methodology; writing – original draft; supervision. Jim Vadolas: Conceptualization; methodology; writing – original draft; supervision. Pornthip Chaichompoo: Conceptualization; investigation; funding acquisition; writing – original draft; methodology; validation; visualization; writing – review and editing; software; formal analysis; project administration; data curation; supervision; resources. FUNDING INFORMATION This work was supported by the National Research Council of Thailand (NRCT) and Mahidol University (N42A650349); Mahidol University (Basic Research Fund: fiscal year 2025; FFMY‐212/2568); National Research Council of Thailand (NRCT) (High‐Potential Research Team GrantProgram; N42A650870); National Research Council of Thailand (NRCT) (N42A670732); and the Royal Golden Jubilee PhD Research Scholarship, the National Research Council of Thailand (NRCT) (NRCT5‐RGJ63012‐133). RT was supported by the Royal Golden Jubilee PhD Research Scholarship, the National Research Council of Thailand (NRCT) (NRCT5‐RGJ63012‐133). CONFLICT OF INTEREST STATEMENT The authors declare no competing interests. ETHICS STATEMENT This study was performed in accordance with the Helsinki declaration and was approved by the Mahidol University Central Institutional Review Board (MU‐CIRB), approval number: COA. No. MU‐CIRB2021/069.2503 (Protocol No. MU‐CIRB 2021/082.1102); and the Human Research Ethics Committee, Nakhonpathom Hospital, approval number: COA. No. 021/2022, 017/2023 and 021/2024 (Protocol No. NPH‐REC No. 009/2022). PATIENT CONSENT STATEMENT Written informed consent for experiments involving human participants (including the use of tissue samples) was obtained from all individual participants included in the study. Supporting information Figure S1. Confocal analysis of neutrophil–platelet interaction. Figure S2. Individual confocal channels of neutrophil–platelet aggregation. Figure S3. Zones of investigation and method for analysis. Figure S4. Unravelling the signalling of neutrophil extracellular trap formation induced by P‐selectin and disulphide HMGB1. Figure S5. Composite image of 20 consecutive fields representing the overall results on NET formation and cell aggregation. Figure S6. Effects of NET inhibitors on stages of NET formation in recombinant P‐selectin induced neutrophils. Figure S7. Effects of NET inhibitors on stages of NET formation in recombinant disulphide HMGB1 induced neutrophils. Table S1. The list of antibodies for flow cytometry and confocal microscopic analysis. Table S2. Primer sequences.